Stockscreener 앱 받기
3.99
3.16%
-0.13
시간 외 거래:
3.95
-0.04
-1.00%
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna stock plunges 28% amid data update on lead drug - MSN
H.C. Wainwright cuts Kyverna stock price target by 14%, keeps Neutral stance - Investing.com
Kyverna stock maintains Neutral rating as analyst revises outlook amid higher costs - Investing.com
Kyverna Therapeutics (NASDAQ:KYTX) Price Target Cut to $6.00 by Analysts at HC Wainwright - MarketBeat
Kyverna Therapeutics Announces New Patient Data Highlighting Pot - GuruFocus.com
What is Leerink Partnrs’ Forecast for KYTX FY2024 Earnings? - Defense World
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop - Yahoo Finance
Wells Fargo & Company Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $24.00 - Defense World
Kyverna's CAR T-Cell Therapy Shows Promising Results in Lupus Nephritis Treatment | KYTX Stock News - StockTitan
Creative Planning Acquires Shares of 11,028 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - StreetInsider.com
(KYTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $28.71 - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in October - MarketBeat
(KYTX) Trading Report - Stock Traders Daily
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S - MarketBeat
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus.com
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors - cnhinews.com
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors | KYTX Stock News - StockTitan
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy - Insider Monkey
(KYTX) Technical Data - Stock Traders Daily
500: Something went wrong - Investing.com
JPMorgan bullish on Kyverna Therapeutics stock amid CAR-T expansion potential - Investing.com UK
7 Best Nano Cap Stocks To Invest In - Insider Monkey
The Kyverna Therapeutics Inc. (KYTX) had a good session last reading, didn’t it? - US Post News
Kyverna Therapeutics Inc. (KYTX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Marshall Wace LLP - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Price Target from Analysts - Defense World
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Target Price from Analysts - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Millennium Management LLC - MarketBeat
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data - Investing.com
Down rounds don’t aid post-IPO performance - BioCentury
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc - GuruFocus.com
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data By Investing.com - Investing.com South Africa
Kyverna Therapeutics (NASDAQ:KYTX) Research Coverage Started at UBS Group - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Lifted to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Market Update: Kyverna Therapeutics Inc. (KYTX) Sees Negative Movement, Closing at 4.89 - The Dwinnex
Novo Holdings A S Acquires 1,050,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Biotech Kyverna Surges 36% in Debut After Boosting IPO Size - MSN
MBB Public Markets I LLC Acquires New Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Deerfield Management Company L.P. Series C Acquires 520,663 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Deerfield Management Company L.P. Series C - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires 9,385 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Affinity Asset Advisors LLC Buys Shares of 200,000 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Affinity Asset Advisors LLC Takes $1.50 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Bank of New York Mellon Corp Purchases Shares of 55,790 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Acquired by Great Point Partners LLC - Defense World
Great Point Partners LLC Increases Stock Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
A Tale of Resilience: Kyverna Therapeutics Inc. Amid Stock Market Turbulence - The InvestChronicle
XTX Topco Ltd Acquires Shares of 83,286 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
ECTRIMS 2024: Driving a fast CAR on the MS road and beyond - BioWorld Online
0.93%
3.55%
자본화:
|
볼륨(24시간):